Form 4: UNITED THERAPEUTICS CEO Sells Shares

Sentiment:

Insider Transaction (Form 4)


Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 29, 2026.

Summary

  • Option exercise/conversion: acquired 9,500 Common Stock at $135.42 ($1,286,490) on July 29, 2026; holds 333,943 after (Indirect).
  • Open-market sale: disposed of 798 Common Stock at $518.25 ($413,565) on July 29, 2026; holds 333,145 after (Indirect).
  • Open-market sale: disposed of 1,112 Common Stock at $519.29 ($577,453) on July 29, 2026; holds 332,033 after (Indirect).
  • Open-market sale: disposed of 900 Common Stock at $520.40 ($468,364) on July 29, 2026; holds 331,133 after (Indirect).
  • Open-market sale: disposed of 1,270 Common Stock at $521.32 ($662,078) on July 29, 2026; holds 329,863 after (Indirect).
  • Open-market sale: disposed of 880 Common Stock at $522.51 ($459,813) on July 29, 2026; holds 328,983 after (Indirect).
  • Open-market sale: disposed of 1,318 Common Stock at $523.62 ($690,138) on July 29, 2026; holds 327,665 after (Indirect).
  • Open-market sale: disposed of 1,982 Common Stock at $524.47 ($1,039,503) on July 29, 2026; holds 325,683 after (Indirect).
  • Open-market sale: disposed of 1,240 Common Stock at $525.46 ($651,575) on July 29, 2026; holds 324,443 after (Indirect).
  • Option exercise/conversion: disposed of 9,500 Stock Option on July 29, 2026; holds 246,410 after (Indirect).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $4,962,488 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Martine A Rothblatt — Director, Officer (Chairperson & CEO)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-07-29Option exercise/conversionCommon Stock9,500$135$1.3M333,943
2026-07-29Open-market saleCommon Stock798$518$413.6K333,145
2026-07-29Open-market saleCommon Stock1,112$519$577.5K332,033
2026-07-29Open-market saleCommon Stock900$520$468.4K331,133
2026-07-29Open-market saleCommon Stock1,270$521$662.1K329,863
2026-07-29Open-market saleCommon Stock880$523$459.8K328,983
2026-07-29Open-market saleCommon Stock1,318$524$690.1K327,665
2026-07-29Open-market saleCommon Stock1,982$524$1.0M325,683
2026-07-29Open-market saleCommon Stock1,240$525$651.6K324,443
2026-07-29Option exercise/conversionStock Option9,500——246,410

Key Dates

DateDescription
2026-07-29Option exercise/conversion (9,500 shares)
2026-07-29Open-market sale (798 shares)
2026-07-29Open-market sale (1,112 shares)
2026-07-29Open-market sale (900 shares)
2026-07-29Open-market sale (1,270 shares)
2026-07-29Open-market sale (880 shares)
2026-07-29Open-market sale (1,318 shares)
2026-07-29Open-market sale (1,982 shares)
2026-07-29Open-market sale (1,240 shares)
2026-07-29Option exercise/conversion (9,500 shares)

Keywords

insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.